PITTSBURGH–(BUSINESS WIRE)–CytoAgents, Inc. a clinical-stage biotechnology company developing CTO1681, a novel, steroid-sparing inhibitor of prostaglandin-mediated inflammation, announced today the appointment of Dr. Johannes Wolff, MD, PhD, as Chief Medical Officer (CMO) and Michael D. Howell,…
PITTSBURGH–(BUSINESS WIRE)–CytoAgents, Inc., a clinical-stage biotechnology company developing CTO1681, a novel, steroid-sparing inhibitor of prostaglandin-mediated inflammation announced today that data from two of its Investigational New Drug (IND) application enabling studies will be presented at…
PITTSBURGH–(BUSINESS WIRE)–CytoAgents, Inc., a clinical-stage biotechnology company developing CTO1681, a novel, steroid sparing inhibitor of prostaglandin mediated inflammation, announced today that preliminary safety data from its Phase 1b/2a clinical trial for its lead drug candidate,…
Providing cures for cancers previously thought uncurable, CAR-T therapies have been a bright success story for cell therapy. But they’re not without their problems: in addition to expensive infrastructure challenges, CAR-T therapies also have to…